The present invention relates to a preparation method for a traditional Chinese medicine drop pill and a traditional Chinese medicine micro drop pill prepared by using the method, and in particular, the present invention relates to a micro drop pill preparation method with high drug-loading capacity, simple preparation process and high production rate and a micro drop pill prepared by using the method. Specially, The drop pill preparation method used comprises the following steps: (1) material melting step: heat melting a medicine and a drop pill matrix to obtain a molten medicine liquid; (2) dropping step: delivering the molten medicine liquid to a dripper, and acquiring medicine drops of the molten medicine liquid by means of vibration dropping; and, (3) condensation step: cooling the medicine drops with a cooling gas to obtain micro drop pills.

The invention provides compositions, methods, and diagnostics for the treatment of metabolic syndromes. In an additional aspect of the invention, compositions and methods of treatment are calibrated to mimic the ileal brake response resulting from surgical intervention, e.g. RYGB, to control metabolic syndrome manifestations and thereby reverse or ameliorate the cardiovascular damage (atherosclerosis, hypertension, lipid accumulation, and the like) resulting from progression of metabolic syndrome. Combination medicaments that act synergistically on the ileal brake and the manifestations of metabolic syndrome are also disclosed.

Compositions for reducing the frequency of urination and methods of manufacture of the compositions are disclosed. One method of manufacture include the steps of forming a first mixture comprising a first active ingredient comprising one or more analgesic, coating the first mixture with a first delayed-release coating to form a first component, forming a second mixture comprising a second active ingredient comprising one or more analgesic agents, coating the second mixture with a second delayed-release coating to form a second component, and combining the first component with the second component to form a third mixture.

Disclosed are colon-specific delayed-release pharmaceutical compositions comprising: a) a matrix wherein micronized menthol with a particle-size distribution ranging between 100 nm and 1200 m is dispersed b) a gastro-resistant or acid-resistant pH-independent coating with a lag time of matrix a).

The present invention provides compositions for delivering an active agent to an animal, comprising an active agent, a first coating, a second coating and a third coating. The active agent is coated with the first coating, the first coating is coated with the second coating, and the second coating is coated with the third coating. The active agent is in contact with the first coating, not the second or third coating. The first coating separates the active agent from the second coating while the second coating separates the first and third coatings. The first, second and third coatings are different from each other. Also provided are methods for making and using the compositions.

The present invention discloses a formulation for slow release of at least one active ingredient, wherein the formulation comprises of at least one active ingredient, at least one matrix forming or coat forming natural compound/component and at least one hardening agent. The formulation of the invention may further comprise an acid.

The present invention is directed to a solid dose form comprising a film coating composition encapsulating a core, wherein: (i) the core comprises an active ingredient comprising at least one of a pharmaceutical, veterinary, or nutraceutical active ingredient; (ii) the film coating composition comprises ethylcellulose and guar gum, wherein the guar gum has an apparent viscosity 151.0 cps at a shear rate of 50 s.sup.1 in a 1% aqueous guar gum solution measured rotationally at 20 C. after 1 minute equilibration using a 6 cm acrylic cone (1) on a cone-plate viscometer wherein the shear is ramped up linearly from 1 to 50 s.sup.1 in 25 steps over 29 seconds; (iii) the dose form provides controlled release of the active ingredient; (iv) the guar gum is present in an amount greater than 5 wt % based on the weight of the guar gum and ethylcellulose; and (v) the dose form is ethanol resistant.

Compositions for reducing the frequency of urination and methods of manufacture of the compositions are disclosed. One method of manufacture include the steps of forming a first mixture comprising a first active ingredient comprising one or more analgesic, coating the first mixture with a first delayed-release coating to form a first component, forming a second mixture comprising a second active ingredient comprising one or more analgesic agents, coating the second mixture with a second delayed-release coating to form a second component, and combining the first component with the second component to form a third mixture.

In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralized, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.

The present invention relates to a stable, immediate release solid oral pharmaceutical compositions comprising iron chelating agents like Deferasirox and at least one pharmaceutical acceptable excipient wherein the composition is free of glidant. Prior art discloses various technical challenges and suggest restrictive and complex solutions for the development of immediate release dosage forms of Deferasirox such as utilizing a large number of excipients or non-conventional formulation techniques. The glidant free immediate release solid oral pharmaceutical composition of Deferasirox, prepared as per present invention exhibited desirable technical attributes like pharmaceutical stability, flow properties and comparable dissolution, bioequivalence against reference listed drug.